ChiCTR2500095282 版本V1.1 版本创建时间2025/02/27 17:28:47 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500095282 

最近更新日期:

Date of Last Refreshed on:

2025-01-04 21:57:33 

注册时间:

Date of Registration:

2025-01-04 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

Sherock 3CG 导管尖端定位系统在PICC 置管中的应用:一项前瞻性、观察性研究

Public title:

Clinical use of Sherlock-3CG? for positioning peripherally inserted central catheter: a prospective observational study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

Sherock 3CG 导管尖端定位系统在PICC 置管中的应用:一项前瞻性、观察性研究

Scientific title:

Clinical use of Sherlock-3CG? for positioning peripherally inserted central catheter: a prospective observational study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

江洁汀 

研究负责人:

黄宏梅 

Applicant:

Jieting Jiang 

Study leader:

Hongmei Huang 

申请注册联系人电话:

Applicant telephone:

+86 150 0070 8712

研究负责人电话:

Study leader's
telephone:

+86 138 8367 0478

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lia0726@foxmail.com

研究负责人电子邮件:

Study leader's E-mail:

985203274@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

贵黔国际总医院

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

贵州省贵阳市乌当区东风大道1号

研究负责人通讯地址:

贵州省贵阳市乌当区东风大道1号

Applicant address:

No.1 Dongfeng Avenue, Wudang District, Guiyang City, Guizhou Province

Study leader's address:

No.1 Dongfeng Avenue, Wudang District, Guiyang City, Guizhou Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

贵黔国际总医院

Applicant's institution:

Guiqian International General Hospital

研究负责人所在单位:

贵黔国际总医院

Affiliation of the Leader:

Guiqian International General Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

贵黔2024伦审第20240027号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

贵黔国际医院伦理委员会

Name of the ethic committee:

Ethic committee of Guiqian International Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-11-26 00:00:00

伦理委员会联系人:

童小波

Contact Name of the ethic committee:

Xiaobo Tong

伦理委员会联系地址:

贵阳市乌当区东风镇东风大道77号贵黔国际医院五楼医务办

Contact Address of the ethic committee:

5th Floor, Medical Affairs Office,No.77 Dongfeng Avenue, Wudang District, Guiyang City, Guizhou Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 851 8627 7666

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

贵黔国际总医院

Primary sponsor:

Guiqian International General Hospital

研究实施负责(组长)单位地址:

贵州省贵阳市乌当区东风大道1号

Primary sponsor's address:

No.1 Dongfeng Avenue, Wudang District, Guiyang City, Guizhou Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

贵州

市(区县):

贵阳

Country:

China

Province:

Guizhou

City:

Guiyang

单位(医院):

贵黔国际总医院

具体地址:

贵州省贵阳市乌当区东风大道1号

Institution
hospital:

Guiqian International General Hospital

Address:

No.1 Dongfeng Avenue, Wudang District, Guiyang City, Guizhou Province

经费或物资来源:

肿瘤科自配

Source(s) of funding:

Self-supplied by the Oncology Department

研究疾病:

无  

Target disease:

Adult patients requiring PICC catheterization

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

观察Sherlock 3CG导管尖端定位系统(3 Complete Integrated Technologies Tip Confrmation System,3CG TCS)在导管尖端位置定位中应用的准确性、安全性及易用性,分析患者基本情况及置管条件、置管人员经验等因素对导管尖端位置定位准确性的影响,同时探索不同资历的PICC(Peripherally Inserted Central Catheter,PICC)专科护士对设备使用过程中的满意度。  

Objectives of Study:

To observe the accuracy, safety and ease of application of Sherlock 3CG Tip Confrmation System (3 Complete Integrated Technologies Tip Confrmation System, 3CG TCS) in catheter tip location. The effects of basic patient conditions, catheterization conditions, and catheterization experience on the accuracy of Catheter tip location were analyzed, and the satisfaction with Peripherally Inserted Central Catheter (PICC) nurses with different seniority during the use of the device was explored.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1: 年龄在18~95岁 2: 符合置管适应症,需要置入PICC 3: 体表心电图有可识别P波 4: 自愿签署知情同意书

Inclusion criteria

1: They are between 18 and 95 years old 2: It meets the catheterization indication and requires PICC insertion 3: The surface electrocardiogram has a recognizable P wave 4: Voluntarily sign informed consent

排除标准:

1: 符合置管禁忌症 2: 凝血机制障碍的患者 3: 有身体残疾、脊柱侧弯等影响身高获得 4: 房颤及心率失常的患者

Exclusion criteria:

1: Contraindications for catheterization 2: Patients with coagulation mechanism disorders 3: There are physical disabilities, scoliosis, etc. that affect height acquisition 4: Patients with atrial fibrillation and arrhythmia

研究实施时间:

Study execute time:

From 2024-12-01 00:00:00 To 2026-06-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-12-01 00:00:00 To 2025-12-31 00:00:00

干预措施:

Interventions:

组别:

传统腔内心电图定位法组

样本量:

163

Group:

Traditional intracavitary electrocardiogram localization group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

组别:

Sherlock 3CG TCS定位法组

样本量:

163

Group:

Sherlock 3CG TCS positioning methodgroup

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

贵州 

市(区县):

 

Country:

China

Province:

Guizhou

City:

单位(医院):

贵黔国际总医院 

单位级别:

三级 

Institution
hospital:

Guiqian International General Hospital

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

准确性

指标类型:

主要指标

Outcome:

Accuracy

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

安全性

指标类型:

次要指标

Outcome:

safety

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

易用性

指标类型:

主要指标

Outcome:

user friendliness

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 95 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2026年6月 百度云网盘https://pan.baidu.com/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

June 2026 Baidu Netdisk https://pan.baidu.com/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

1.数据收集方法 我们将使用标准化的病例报告表(CRF)来收集所有参与者的数据。CRF将包括人口统计学信息、基线特征、干预措施、随访结果以及任何不良事件。 2.数据录入和管理 所有数据将双人使用EDIDATA录入和管理,以确保数据的准确性和完整性。 3.数据质量控制 管理人员将定期进行纸质问卷中数据的核查,以识别和纠正错误。 4.数据安全和保密 所有数据将存储在安全的服务器上,并采用加密技术保护数据不被未经授权的访问。 只有经过授权的研究团队成员才能访问数据,并且所有数据的使用都将遵守相关法律法规和伦理标准。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

1. Data Collection Methods We will use a standardized case report form (CRF) to collect data from all participants.The CRF will include demographic information, baseline characteristics, interventions, follow-up outcomes, and any adverse events. 2. Data entry and management All data will be entered and managed in pairs using EDIDATA to ensure data accuracy and completeness. 3. Data Quality Control Verification of data in paper questionnaires will be carried out periodically by the administrators to identify and correct errors. 4.Data Security and Confidentiality All data will be stored on a secure server with encryption technology to protect the data from unauthorized access. Only authorized members of the research team will have access to the data and all data will be used in compliance with relevant laws, regulations and ethical standards.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2025-01-04 21:56:57